结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019)

2019-08-30 中国医师协会结直肠肿瘤专委会 腹膜肿瘤专业委员会 中华结直肠疾病电子杂志.2019,8(4):329-335.

我国结直肠癌发病率和死亡率均位于恶性肿瘤的前列,腹膜转移作为常见转移部位,是治疗失败的常见原因之一。目前结直肠癌腹膜转移的腹腔预防和治疗性药物种类繁多,但作用剂量和时间尚未形成规范化的治疗模式。因此为了规范术中预防和治疗性腹腔干预方法,中国医师协会结直肠肿瘤专业委员会组织国内相关领域权威专家,制定《结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识》(以下简称《共识》),旨在提高我国结直肠肿瘤的整体诊

中文标题:

结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019)

发布日期:

2019-08-30

简要介绍:

我国结直肠癌发病率和死亡率均位于恶性肿瘤的前列,腹膜转移作为常见转移部位,是治疗失败的常见原因之一。目前结直肠癌腹膜转移的腹腔预防和治疗性药物种类繁多,但作用剂量和时间尚未形成规范化的治疗模式。因此为了规范术中预防和治疗性腹腔干预方法,中国医师协会结直肠肿瘤专业委员会组织国内相关领域权威专家,制定《结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识》(以下简称《共识》),旨在提高我国结直肠肿瘤的整体诊治水平,延长结直肠癌患者生存时间并改善生活质量。

 

拓展指南:结直肠癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019))] GetToolGuiderByIdResponse(projectId=1, id=750771c001e887bd, title=结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019), enTitle=, guiderFrom=中华结直肠疾病电子杂志.2019,8(4):329-335., authorId=null, author=, summary=我国结直肠癌发病率和死亡率均位于恶性肿瘤的前列,腹膜转移作为常见转移部位,是治疗失败的常见原因之一。目前结直肠癌腹膜转移的腹腔预防和治疗性药物种类繁多,但作用剂量和时间尚未形成规范化的治疗模式。因此为了规范术中预防和治疗性腹腔干预方法,中国医师协会结直肠肿瘤专业委员会组织国内相关领域权威专家,制定《结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识》(以下简称《共识》),旨在提高我国结直肠肿瘤的整体诊, cover=, journalId=null, articlesId=null, associationId=1547, associationName=中国医师协会结直肠肿瘤专委会 腹膜肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Fri Aug 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>我国结直肠癌发病率和死亡率均位于恶性肿瘤的前列,腹膜转移作为常见转移部位,是治疗失败的常见原因之一。目前结直肠癌腹膜转移的腹腔预防和治疗性药物种类繁多,但作用剂量和时间尚未形成规范化的治疗模式。因此为了规范术中预防和治疗性腹腔干预方法,中国医师协会结直肠肿瘤专业委员会组织国内相关领域权威专家,制定《结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识》(以下简称《共识》),旨在提高我国结直肠肿瘤的整体诊治水平,延长结直肠癌患者生存时间并改善生活质量。 </P> <P> </P>拓展指南:<strong>与<font color=red>结直肠癌</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=1358a1c001e809b7" title="NCCN临床实践指南:结直肠癌筛查(2019.V2)" target=_blank>NCCN临床实践指南:结直肠癌筛查(2019.V2)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=f75fa1c001e67798" title="2019 ASCO资源分层指南:早期结直肠癌患者的治疗" target=_blank>2019 ASCO资源分层指南:早期结直肠癌患者的治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=cd7121c001e67680" title="2019 ASCO资源分层指南:结直肠癌的早期检测" target=_blank>2019 ASCO资源分层指南:结直肠癌的早期检测</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=f5bb01c001e6369d" title="结直肠癌围手术期营养治疗中国专家共识(2019版)" target=_blank>结直肠癌围手术期营养治疗中国专家共识(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=992351c001e61355" title="2019 年结直肠癌肝转移诊疗指南最新解读" target=_blank>2019 年结直肠癌肝转移诊疗指南最新解读</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E7%BB%93%E7%9B%B4%E8%82%A0%E7%99%8C" target=_blank>有关结直肠癌更多指南</a></ul>, tagList=[TagDto(tagId=94289, tagName=结直肠癌腹膜转移), TagDto(tagId=94290, tagName=腹腔用药)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=18601, appHits=250, showAppHits=0, pcHits=16979, showPcHits=2324, likes=78, shares=9, comments=3, approvalStatus=1, publishedTime=Sun Sep 08 23:29:21 CST 2019, publishedTimeString=2019-08-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Sep 08 23:29:21 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:31:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019))])
结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019)
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1069747, encodeId=ee4c1069e4734, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f16f5708737, createdName=ms8000001300645534, createdTime=Fri Nov 12 21:28:56 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925596, encodeId=c41892559679, content=已阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210219/f170b7f2eb014d5d88660a74670c7d49/95bdcd8f1c754b198534303baddb0d7d.jpg, createdBy=4a6e5461309, createdName=合欢花, createdTime=Fri Feb 19 22:32:45 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372781, encodeId=f9783e2781c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Sep 16 06:41:44 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2021-11-12 ms8000001300645534

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1069747, encodeId=ee4c1069e4734, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f16f5708737, createdName=ms8000001300645534, createdTime=Fri Nov 12 21:28:56 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925596, encodeId=c41892559679, content=已阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210219/f170b7f2eb014d5d88660a74670c7d49/95bdcd8f1c754b198534303baddb0d7d.jpg, createdBy=4a6e5461309, createdName=合欢花, createdTime=Fri Feb 19 22:32:45 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372781, encodeId=f9783e2781c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Sep 16 06:41:44 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2021-02-19 合欢花

    已阅读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1069747, encodeId=ee4c1069e4734, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f16f5708737, createdName=ms8000001300645534, createdTime=Fri Nov 12 21:28:56 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925596, encodeId=c41892559679, content=已阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210219/f170b7f2eb014d5d88660a74670c7d49/95bdcd8f1c754b198534303baddb0d7d.jpg, createdBy=4a6e5461309, createdName=合欢花, createdTime=Fri Feb 19 22:32:45 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372781, encodeId=f9783e2781c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Sep 16 06:41:44 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 thm112988

    0